Mizuho analyst Steven Valiquette lowered the firm’s price target on LifeMD (LFMD) to $6 from $8 and keeps a Neutral rating on the shares. The company’s Q3 revenue and EBITDA missed estimates as its virtual weight management program saw greater competitive pressure from compounded GLP-1 marketers, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFMD: